Press

2024-02-23

Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the fourth quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 17,1 million (SEK 11,6 million). Operating income amounted to SEK -18,5 million (SEK -14,0...

Read More
2023-11-17

Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the third quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 9,2 million (SEK 8,7 million). Operating income for the third quarter amounted to SEK...

Read More
2023-05-19

Interim Report First Quarter 2023 January 1 – March 31 2023 Kancera AB (publ.), org.no. 556806-8851

The period in briefJanuary – MarchFinancial summary for the first quarter• Net sales amounted to SEK 0 million (SEK 0).• R&D expenses amounted to SEK 15,2 million (SEK10,6 million).• Operating profit for the first quarter amounted to SEK -17.2...

Read More
2022-10-20

Kancera reports promising preclinical results from studies of its Fractalkine axis blocking drug candidates in B-cell lymphoma

Kancera AB (publ) reports new preclinical results supporting the potential for the company’s Fractalkine axis blocking candidate drugs to increase the efficacy of standard-of-care drug treatment of B-cell lymphomas, such as chronic lymphocytic leukemia (CLL).

Read More
2021-12-06

Kancera appoints Peter Selin as Executive Vice President Corporate Development

Kancera AB (publ) today announces that Peter Selin has been appointed as Executive Vice President Corporate Development, responsible for business development, strategic partnerships and licensings. He will be part of the management team and report directly to the CEO.

Read More
2021-04-21

Kancera provides an update on the development of the company’s pharmaceutical project and nominates a new drug candidate

two thirds of patients have now been dosed in the clinical study of KAND567 for the treatment of COVID-19; patient recruitment is expected to be completed during the current quarter, successful scaling up of production of the drug candidate...

Read More
2016-08-19

Interim Report for Kancera AB (publ) Q2 2016 January 1 – June 30, 2016

As a consequence of the acquisition of the subsidiary Kancera Förvaltning AB on 2016-06-16, the present Interim Report, Q2 2016, is prepared in accordance with IAS 34 and related parts of the Annual Accounts Act. The consolidated financial statements...

Read More
2016-05-03

Interim Report for Kancera AB (publ) Q1 2016, January 1 – March 31, 2016

The period January to March 2016 in brief R&D expenses for the period amounted to SEK 4.2m (SEK 4.2m). Operating income for the period amounted to SEK -5.1m (SEK 4.9m). Income after financial items for the period amounted to...

Read More
2016-02-19

Interim Report for Kancera AB (publ) Q4 2015, January 1 – December 31, 2015

The period January to December 2015 and the fourth quarter 2015 in brief R&D expenses for the period amounted to SEK 20.4m (SEK 13.7m) of which the fourth quarter constituted SEK 8.3m (SEK 4.1m). Following EU’s approval of Kancera’s...

Read More
2015-11-20

Interim Report for Kancera AB (publ) Q3 2015. January 1 – September 30, 2015.

The period January to September 2015 and the third quarter 2015 in brief R&D expenses for the period amounted to SEK 12.1m (SEK 9.6m) of which the third quarter constituted SEK 3.2m (SEK 2.7m). Operating income for the period...

Read More